A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Trial to Assess the Efficacy, Safety and Tolerability of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Myocardium, Using an Endomyocardial Delivery System

The purpose of this study is to evaluate the safety and effectiveness of injecting myoblasts (grown from your own skeletal muscle), using a catheter device, directly into the damaged heart muscle for treatment of severe heart failure.

Start Date01 Mar 2008

Sponsor / Collaborator

Mytogen, Inc.

100 Clinical Results associated with Myoblast(Mytogen)

100 Translational Medicine associated with Myoblast(Mytogen)

100 Patents (Medical) associated with Myoblast(Mytogen)

Literatures (Medical) associated with Myoblast(Mytogen)

01 Oct 2004·The Biological BulletinQ4 · BIOLOGY

Characterization of the Myostatin-Like Gene in Argopecten irradians

Q4 · BIOLOGY

Article

Author: Roberts, Steven ; Bissonnette, Adam

The bay scallop, Argopecten irradians, is a marine bivalve with significant commercial and scientific importance, primarily as a result of the species’ large adductor muscle. Recently, a myostatin-like transcript (sMSTN) has been isolated from this species. Myostatin is a member of the transforming growth factor superfamily and has been shown to be an important negative regulator of muscle growth in several vertebrate species. To date, the function of the myostatin-like gene in invertebrates is undetermined. Therefore, the purpose of the present study was to further understand the role of this gene by 1) determining genomic structure of sMSTN and 2) quantifying the effects of treating bay scallops with a myostatin inhibitor (Myo-Blast: Cytodyne). To determine the genomic structure, a nested PCR-based genome-walking technique was performed. Briefly, oligonucleotide primers were designed corresponding to the 5 and 3 -ends of sMSTN; and together with arbitrary primers (DW-ACP1, 2, 3, and 4 SeeGene), two major PCR products were amplified ( 1500 bp). The second approach was carried out on two groups of animals: experimentals and controls (n 15, each). For three days, during two 2-hour treatment sessions per day, the two groups of animals were placed in containers containing non-flowing, but aerated, ambient seawater. Myo-Blast powder suspended in 250 ml of seawater was added to the experimental containers, while the controls received seawater only. After the three days of treatment, a differential display technique was used to identify the genes that had been regulated in the treated scallops, but not in the controls. Initial results indicate that a cyclin-T homologue in bay scallops is down-regulated in treated animals, suggesting possible differences in cell cycle activity between treated and control bay scallops. These results suggest that the MSTN gene has been conserved through evolution and could function via a molecular mechanism similar to that observed in mammals. The work described here was supported by USDA grant 2003-35206-12834 (to SBR). Reference: Biol. Bull. 207: 167. (October 2004) © 2004 Marine Biological Laboratory

01 Oct 2004·The Biological BulletinQ4 · BIOLOGY

Use of the Split-Ubiquitin Two-Hybrid System to Identify Proteins Interacting With the Alzheimer Proteins APP and LRP

Q4 · BIOLOGY

Article

Author: Vitale, Rebecca ; Buxbaum, Joseph D.

The bay scallop, Argopecten irradians, is a marine bivalve with significant commercial and scientific importance, primarily as a result of the species’ large adductor muscle. Recently, a myostatin-like transcript (sMSTN) has been isolated from this species. Myostatin is a member of the transforming growth factor superfamily and has been shown to be an important negative regulator of muscle growth in several vertebrate species. To date, the function of the myostatin-like gene in invertebrates is undetermined. Therefore, the purpose of the present study was to further understand the role of this gene by 1) determining genomic structure of sMSTN and 2) quantifying the effects of treating bay scallops with a myostatin inhibitor (Myo-Blast: Cytodyne). To determine the genomic structure, a nested PCR-based genome-walking technique was performed. Briefly, oligonucleotide primers were designed corresponding to the 5- and 3-ends of sMSTN; and together with arbitrary primers (DW-ACP1, 2, 3, and 4 - SeeGene), two major PCR products were amplified (1500 bp). The second approach was carried out on two groups of animals: experimentals and controls (n 15, each). For three days, during two 2-hour treatment sessions per day, the two groups of animals were placed in containers containing non-flowing, but aerated, ambient seawater. Myo-Blast powder suspended in 250 ml of seawater was added to the experimental containers, while the controls received seawater only. After the three days of treatment, a differential display technique was used to identify the genes that had been regulated in the treated scallops, but not in the controls. Initial results indicate that a cyclin-T homologue in bay scallops is down-regulated in treated animals, suggesting possible differences in cell cycle activity between treated and control bay scallops. These results suggest that the MSTN gene has been conserved through evolution and could function via a molecular mechanism similar to that observed in mammals. The work described here was supported by USDA grant 2003-35206-12834 (to SBR).

100 Deals associated with Myoblast(Mytogen)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infarction	Phase 2	US	Mytogen, Inc.	01 Mar 2008
Ischemic cardiomyopathy	Phase 2	US	Mytogen, Inc.	01 Mar 2008
Myocardial injury	Phase 2	US	Mytogen, Inc.	01 Mar 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Myoblast(Mytogen)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation